Toronto Dominion Bank’s Haemonetics HAE Stock Holding History

Toronto Dominion Bank’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200	Closed	-$14.3K	–	2239
2025 Q4	$14.3K	Buy	+200	New	+$13.4K	﹤0.01%	1800

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Toronto Dominion Bank's HAE Position: Q4 2023 in Review

Toronto Dominion Bank sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 9 shares — an estimated $806 sold.

Toronto Dominion Bank first reported a position in HAE in Q2 2020 and held it in 7 quarters. The position peaked at $480K in Q1 2022. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

Toronto Dominion Bank reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
Toronto Dominion Bank sold 9 Haemonetics shares in Q4 2023, an estimated $806.
Toronto Dominion Bank first reported a position in Haemonetics in Q2 2020 and held it in 7 quarters.
Toronto Dominion Bank's Haemonetics position peaked at $480K in Q1 2022.
295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Toronto Dominion Bank's 13F filing for Q4 2023, filed 13 Feb 2024.